They designed a validation cohort of 19 NSCLC patients receiving anti-PD-1 agents, and they found that responders had significantly decreased levels of serum IL-8 at the best response moment, whereas non-responders presented opposite changes. Here, CXCL8 is linked to non-small cell lung carcinoma.